138 related articles for article (PubMed ID: 10325501)
1. Evaluation of biomarker modulation by fenretinide in prostate cancer patients.
Urban D; Myers R; Manne U; Weiss H; Mohler J; Perkins D; Markiewicz M; Lieberman R; Kelloff G; Marshall M; Grizzle W
Eur Urol; 1999; 35(5-6):429-38. PubMed ID: 10325501
[TBL] [Abstract][Full Text] [Related]
2. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions.
Hoedemaeker RF; Kranse R; Rietbergen JB; Kruger AE; Schröder FH; van der Kwast TH
Cancer; 1999 Jan; 85(1):145-52. PubMed ID: 9921986
[TBL] [Abstract][Full Text] [Related]
4. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.
Gee JR; Saltzstein DR; Messing E; Kim K; Kolesar J; Huang W; Havighurst TC; Harris L; Wollmer BW; Jarrard D; House M; Parnes H; Bailey HH
Eur J Cancer Prev; 2016 Jul; 25(4):312-20. PubMed ID: 26313229
[TBL] [Abstract][Full Text] [Related]
8. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
9. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration.
Thaller C; Shalev M; Frolov A; Eichele G; Thompson TC; Williams RH; Dillioglugil O; Kadmon D
J Clin Oncol; 2000 Nov; 18(22):3804-8. PubMed ID: 11078493
[TBL] [Abstract][Full Text] [Related]
10. Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer.
Weiss HL; Urban DA; Grizzle WE; Cronin KA; Freedman LS; Kelloff GJ; Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):220-3. PubMed ID: 11295632
[TBL] [Abstract][Full Text] [Related]
11. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy?
Naya Y; Ayala AG; Tamboli P; Babaian RJ
Urology; 2004 Mar; 63(3):503-8. PubMed ID: 15028446
[TBL] [Abstract][Full Text] [Related]
12. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).
Webber MM; Bello-DeOcampo D; Quader S; Deocampo ND; Metcalfe WS; Sharp RM
Clin Exp Metastasis; 1999 May; 17(3):255-63. PubMed ID: 10432011
[TBL] [Abstract][Full Text] [Related]
14. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.
Gee J; Bailey H; Kim K; Kolesar J; Havighurst T; Tutsch KD; See W; Cohen MB; Street N; Levan L; Jarrard D; Wilding G
Prostate; 2013 Jun; 73(9):970-8. PubMed ID: 23335089
[TBL] [Abstract][Full Text] [Related]
15. PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy.
Morote J; Fernández S; Alaña L; Iglesias C; Planas J; Reventós J; Ramón Y Cajal S; Paciucci R; de Torres IM
Clin Cancer Res; 2008 May; 14(9):2617-22. PubMed ID: 18451224
[TBL] [Abstract][Full Text] [Related]
16. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
17. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
18. Expression of proinflammatory cytokine interleukin-6 in tissue samples of human prostate obtained by needle biopsy.
Miličević N; Mrčela M; Galić J; Marjanović K
Pathol Res Pract; 2015 Nov; 211(11):865-70. PubMed ID: 26376467
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
20. High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population.
Gokden N; Roehl KA; Catalona WJ; Humphrey PA
Urology; 2005 Mar; 65(3):538-42. PubMed ID: 15780372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
